Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.
about
Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer.Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor modelAdoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantationRituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptorsCord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case reportTherapeutic vaccine against DPP4 improves glucose metabolism in miceGA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is presentNatural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic lComparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus.Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways.Combination therapy with the type II anti-CD20 antibody obinutuzumab.[Researche advances on CIK cells and their clinical use in lung cancer].Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen
P2860
Q33429758-703BF2C8-CC7A-4007-B95B-DBEC02A191B3Q33875615-0C4EE772-78CC-4B5C-ADCC-FD04D4002769Q34427459-16C06B83-62C0-45EB-AEE1-023073CE4C6BQ35218943-3723F1F4-AADC-4603-B170-BD0BF8B33A56Q36102906-DF86A302-B121-47E3-BE2C-2BB78C7A9F7DQ36153869-B2F6D189-A30C-4DCE-A321-0D141E7DDCF4Q37687552-F65EF95D-FF10-4E98-A476-D6849568BB3DQ38315579-47168316-7BDF-4089-9EF1-10969BD16F2CQ38542034-90FFF094-99F0-4A89-A35A-CAB49C5A5995Q38827226-B53ED1A2-FA36-42BD-964F-AA104B7BDDE4Q38827600-0CCF10A4-4FAB-4C5B-BB75-BBA6422EEFA7Q39192585-2808F957-22A0-4D4F-BAD5-6FF4461DD594Q41702562-A9B12C47-71EF-48AF-80E9-50D6A73B4E4DQ43180780-AB5B95F8-4ED3-464E-B42D-4BF51CDB9C5EQ47898168-8BA76306-8B2C-48DC-BF2A-BD5E6FF0B0A1Q55504567-147925E4-9A09-4B41-B52F-8A1CBEC752FAQ59126075-125A77F0-20A3-4F6C-8C6C-26EC1D7C64AD
P2860
Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Enhanced killing of human B-ce ...... ures and anti-CD20 antibodies.
@en
Enhanced killing of human B-ce ...... f cytokine-induced killer cell
@nl
type
label
Enhanced killing of human B-ce ...... ures and anti-CD20 antibodies.
@en
Enhanced killing of human B-ce ...... f cytokine-induced killer cell
@nl
prefLabel
Enhanced killing of human B-ce ...... ures and anti-CD20 antibodies.
@en
Enhanced killing of human B-ce ...... f cytokine-induced killer cell
@nl
P2093
P1433
P1476
Enhanced killing of human B-ce ...... tures and anti-CD20 antibodies
@en
P2093
Alessandro Rambaldi
Alice Pievani
Camilla Belussi
Christian Klein
P304
P356
10.1182/BLOOD-2010-06-290858
P407
P577
2010-11-03T00:00:00Z